Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
IMNN Stock Chart & Stats
$3.87
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.87
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$3.56 - $41.22
Previous CloseN/A
Volume151.93K
Average Volume (3M)131.31K
Market Cap
$11.91M
Enterprise Value$11.79M
Total Cash (Recent Filing)$5.25M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Mar 26, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding3,070,354
10 Day Avg. Volume100,527
30 Day Avg. Volume131,312
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.96
Price to Sales (P/S)0.00
P/FCF Ratio-0.67
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.43
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$12.00Price Target Upside210.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory AdvantagesIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.
Strategic FinancingImunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.
Therapeutic EfficacyIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.
Bears Say
Funding ChallengesThe company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.
Regulatory RiskThe trial's design includes interim analyses which could lead to an earlier active readout, potentially accelerating the approval process.
Trial ComplexityAdditional trial sites are expected to activate shortly, with an estimated total of ~45 sites, indicating a broad and robust study.
Imunon News
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $3.56 and its highest was $41.22 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $11.91M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Mar 26, 2026 which is in 97 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.199 by $0.039.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.79.
How many shares outstanding does Imunon have?
Imunon has 3,070,354 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.199. Following the earnings report the stock price went up 5.316%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
IMNN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call painted a positive picture with significant progress in clinical trials and strategic planning. Despite financial constraints, the company has managed to achieve regulatory endorsements and reduce operating costs significantly. The successful engagement with the scientific community and regulatory bodies adds to the optimistic outlook, although financial limitations remain a concern.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$12.00
▲(210.08% Upside)
Technical Analysis
Kazia Therapeutics
―
Phio Pharmaceuticals
―
Genprex
―
Galecto
―
TransCode Therapeutics
―
Ownership Overview
12.23% Insiders
0.31% Mutual Funds
2.91% Other Institutional Investors
84.23% Public Companies and Individual Investors
Options Prices
Currently, No data available
---